The present Competitive Intelligence Report about Antibody Therapy of Inflammatory and Autoimmune Diseases provides a competitor evaluation in the field of antibody therapeutics used or being developed for treatment of rheumatoid arthritis, psoriasis, Crohn' s disease, ulcerative colitis, multiple sclerosis, asthma and other autoimmune diseases as of December 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Inflammatory and autoimmune diseases are one of the major indication areas for the use of therapeutic antibodies. The commercial success of anti-TNF antibodies highlights the broad applicability of inflammatory targets to develop antibody therapeutics. Sales of anti-inflammatory and anti-autoimmune antibodies in 2009 exceeded US$ 21 bln. Inflammatory diseases with significant commercial potential as demonstrated by approvals of antibody therapeutics are rheumatoid arthritis and related diseases (psoriatic arthritis, ankylosing spondylitis, juvenile arthritis), psoriasis, Crohn' s disease and ulcerative colitis, but also multiple sclerosis and asthma. Rare indications such as paroxysmal nocturnal hemoglubinuria turned out to be attractive markets for anti-inflammatory antibody therapy. Among the emerging indications for anti-inflammatory antibody therapy are systemic lupus erythematosus. The rare autoimmune diseases benefit from antibodies approved for lead indications in follow-up programs, at least for clinical evaluation.
The report includes a compilation of currently active projects in research and development of antibody therapeutic for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of anti-inflammatory and anti-autoimmune antibodies. Competitor projects are listed in a tabular format providing information on: